Tetraneuron S.L.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tetraneuron S.L. - overview
Established
2012
Location
Madrid, -, Spain
Primary Industry
Pharmaceuticals
About
Based in Spain, and founded in 2012, Tetraneuron S. L. operates as a drug development company that offers gene therapy solutions. The company is a spin-off of the Cajal Institute (CSIC) and had a founding partner, Jose M.
Frade. In December 2025, Tetraneuron S. L. raised EUR 5 million amount of venture funding from GIMIC Ventures and Johnson & Johnson Innovation.
Tetraneuron provides AAV (adenovirus vector)-based E2F4DN-based gene therapy solutions for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company offers the biomarker E2F4 for the early detection of Alzheimer's disease. The company plans to use the funds raised in December 2025 to take the final steps before entering clinical trials and submit a Clinical Trial Application in Europe.
Current Investors
Région Sud Investissement, Valencia Institute of Finance, Johnson & Johnson Innovation
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Biotechnology, Molecular Science, Genetics & Gene Therapy, Pharmaceuticals, Pharmaceutical Research & Development
Website
www.tetraneuron.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.